読み込み中
HKSEHealthcareDrug Manufacturers - Specialty & Generic
最新データ
HK$3.80
−HK$0.025 · -0.65%
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
最新データ
HK$3.80
−HK$0.025 · -0.65%
日中の時刻はHKTです。市場データは遅延する場合があります。
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
日中レンジ
現在 HK$3.80
52週レンジ
現在 HK$3.80
日中の時刻はHKTです。市場データは遅延する場合があります。
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
日中レンジ
現在 HK$3.80
52週レンジ
現在 HK$3.80
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（CNY） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 54.79億 CNY | 52.81億 CNY | 54.46億 CNY | 71.59億 CNY | 63.65億 CNY |
| 売上原価 | 37.36億 CNY | 35.25億 CNY | 36.45億 CNY | 48.25億 CNY | 43.32億 CNY |
| 粗利益 | 17.43億 CNY | 17.56億 CNY | 18億 CNY | 23.34億 CNY | 20.33億 CNY |
| 研究開発 | 2.26億 CNY | 2.12億 CNY | 1.85億 CNY | 2.52億 CNY | 2.21億 CNY |
| 販売・一般管理 | 4.78億 CNY | 4.55億 CNY | 5.9億 CNY | 6.65億 CNY | 5.73億 CNY |
| 営業費用 | 11.07億 CNY | 10.15億 CNY | 26.61億 CNY | 12.12億 CNY | 10.69億 CNY |
| 受取利息 | 3827.05万 CNY | 4437.49万 CNY | 3952.15万 CNY | 5413.86万 CNY | 5485.69万 CNY |
| 支払利息 | 7143.9万 CNY | 1.41億 CNY | 2.23億 CNY | 2.35億 CNY | 2.02億 CNY |
| 減価償却費と償却費 | 3.73億 CNY | 3.31億 CNY | 3.74億 CNY | 3.08億 CNY | 3.03億 CNY |
| 営業利益 | 6.36億 CNY | 7.41億 CNY | −2.38億 CNY | 11.35億 CNY | 7.73億 CNY |
| 純利益 | 3.49億 CNY | 6.47億 CNY | −7.83億 CNY | 7.27億 CNY | 2.41億 CNY |
会社概要が更新されました 2026年10月6日.
直近の発表実績
直近の発表実績
分割調整後の1株当たりの年間現金分配金。
HK$0.2717
2025年（通年）+50.9% 以来 2021
2026年（一部）：HK$0.166
HK$0.18
2,021
HK$0.0411
2,022
HK$0.1122
2,023
HK$0.2717
2,025
HK$0.166
2,026*
* 利用可能な配当履歴のうち、暦年の一部のみを含みます。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 2026年5月27日 | HK$0.166Annual | 2026年5月28日 | 2026年6月18日 |
配当 | 2025年5月26日 | HK$0.2717Annual | 2025年5月27日 | 2025年7月22日 |
配当 | 2023年5月24日 | HK$0.1122Annual | 2023年5月25日 | 2023年8月15日 |
配当 | 2022年6月14日 | HK$0.0411Annual | 2022年6月15日 | 2022年8月15日 |
配当 | 2021年5月28日 | HK$0.18Annual | 2021年5月31日 | 2021年7月26日 |
配当落ち 2026年5月27日
HK$0.166
Annual
2026年5月28日基準 · 支払日 2026年6月18日
配当落ち 2025年5月26日
HK$0.2717
Annual
2025年5月27日基準 · 支払日 2025年7月22日
配当落ち 2023年5月24日
HK$0.1122
Annual
2023年5月25日基準 · 支払日 2023年8月15日
配当落ち 2022年6月14日
HK$0.0411
Annual
2022年6月15日基準 · 支払日 2022年8月15日
配当落ち 2021年5月28日
HK$0.18
Annual
2021年5月31日基準 · 支払日 2021年7月26日
この株式へのエクスポージャーを報告している上場投資信託です。
Dimensional - Emerging Markets Core Equity 2 ETFDFEM10.97万0.00%97.75億 USD0.39%$40.80+1.22%
Dimensional - Emerging Core Equity Market ETFDFAE7.51万0.00%102.6億 USD0.29%$40.40+1.35%
Dimensional World ex U.S. Core Equity 2 ETFDFAX4.61万0.00%124.35億 USD0.28%$37.45+0.46%
Dimensional - Emerging Markets Value ETFDFEV3.68万0.00%22.09億 USD0.46%$43.32+0.60%
Vanguard Total International Stock ETFVXUS1.1万—6657億 USD0.05%$85.85+0.49%
Vanguard Total World Stock ETFVT8528.570.00%1017億 USD0.06%$160.11+0.62%Dimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEDimensional World ex U.S. Core Equity 2 ETFDFAXDimensional - Emerging Markets Value ETFDFEVVanguard Total International Stock ETFVXUSVanguard Total World Stock ETFVTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
